FBLG FibroBiologics, Inc.

NASDAQ
$0.71

FibroBiologics, Inc. (FBLG) is expected to report earnings on February 15, 2027, after the market close. The consensus earnings estimate is a loss of $0.63 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -24.2% since its last earnings release on November 16, 2026.

FibroBiologics Beat Consensus Estimates
Monday, November 16, 2026 · 4:13 PM ET
Earnings Date
4th Quarter, Dec 2026
Feb 15
Monday · 5:35 PM ET
Earnings Whisper
-
vs ($0.63)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $0.83

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About FibroBiologics, Inc.

FibroBiologics Inc. is a cell therapy, regenerative medicine company developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics Inc. is based in HOUSTON.

Sector

Healthcare

Industry

Biotechnology

Charts powered in part by Lightweight Charts™ by TradingView.